Thomas-Duythuc To, MD
Cardiovascular Disease · Reno, NVNPI 1215129044
Payments from drug & device makers
Across 849 payments — averaging $1310.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$299K
- Bayer$283K
- Abbott$275K
- Merck$156K
- Boehringer Ingelheim$37K
- AstraZeneca$33K
- plus $30K from 25 others
What the payments were for
- Consulting fees$55,41516%
- Speaking & faculty fees$214,78863%
- Travel & lodging$37,15411%
- Food & beverage$31,0199%
- Education$1890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 50 | $298,520 |
| Bayer | 216 | $283,300 |
| Abbott | 277 | $275,205 |
| Merck | 35 | $156,010 |
| Boehringer Ingelheim | 49 | $37,270 |
| AstraZeneca | 29 | $32,750 |
| Lilly USA, LLC | 14 | $16,292 |
| Medtronic(2 entities) | 27 | $2,635 |
| Organon | 1 | $2,500 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $1,751 |
| Boston Scientific | 40 | $1,557 |
| Abiomed | 20 | $1,118 |
| Cvrx, Inc. | 10 | $831 |
| Novo Nordisk | 7 | $386 |
| Edwards Lifesciences | 3 | $370 |
| Shockwave Medical, Inc | 4 | $354 |
| Lexicon Pharmaceuticals, Inc. | 5 | $267 |
| Impulse Dynamics (USA) Inc. | 2 | $241 |
| E.r. Squibb & Sons, L.L.C. | 3 | $232 |
| Angiodynamics, Inc. | 1 | $187 |
| Scpharmaceuticals Inc. | 5 | $163 |
| Esperion Therapeutics, Inc. | 2 | $137 |
| ZOLL Respicardia, Inc. | 1 | $134 |
| Amgen | 4 | $100 |
| Alnylam Pharmaceuticals Inc. | 2 | $99 |
| Johnson & Johnson | 4 | $69 |
| Pfizer | 3 | $63 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Atricure, Inc. | 1 | $25 |
| Endotronix, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$204,258
- JARDIANCE$52,889
- VERQUVO$17,431
- ENTRESTO$13,366
- CARDIOMEMS$7,101
- CardioMEMS HF System$6,395
- FARXIGA$4,025
- HeartMate 3 Left Ventricular Assist Device$4,014
- VenaSeal$1,276
- LEQVIO$782
- HeartMate II LVAS$654
- MitraClip$546
- Impella$494
- LifeVest$471
- Barostim Neo System$407
- OPTIMIZER$308
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$297
- AMPLATZER AMULET$284
- AVVIGO Guidance System$262
- ClosureFast$261
How this compares
$1,112,642 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 819 | $1,129,142 |
| EntrestoSacubitril/Valsartan | 521 | $705,900 |
| EliquisApixaban | 388 | $507,707 |
| XareltoRivaroxaban | 214 | $288,573 |
| FarxigaDapagliflozin Propanediol | 164 | $199,029 |
| KerendiaFinerenone | 103 | $142,458 |
| Repatha SureclickEvolocumab | 85 | $87,635 |
| Praluent PenAlirocumab | 69 | $59,661 |
| VerquvoVericiguat | 46 | $54,828 |
| NexlizetBempedoic Acid/Ezetimibe | 54 | $53,592 |
| MounjaroTirzepatide | 23 | $24,698 |
| Rosuvastatin Calcium | 790 | $19,401 |
| Atorvastatin Calcium | 994 | $18,305 |
| Metoprolol Succinate | 629 | $13,736 |
| NexletolBempedoic Acid | 17 | $11,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Pradaxa | $37,270 | $1,132,297832 claims |
| NovartisEntresto | $298,520 | $705,900521 claims |
| PfizerEliquis | $63 | $507,707388 claims |
| Johnson & JohnsonXarelto | $69 | $288,573214 claims |
| AstraZenecaFarxiga | $32,750 | $199,029164 claims |
| BayerKerendia | $283,300 | $142,458103 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $137 | $65,43971 claims |
| MerckVerquvo | $156,010 | $54,82846 claims |
| Lilly USA, LLCMounjaro | $16,292 | $24,69823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Reno
- Joseph StevensonReno$363K
- Christopher RowanReno$280K
- Jay MasonReno$227K
- Devang DesaiReno$206K
- Ram ChallapalliReno$18K
- Anita KediaReno$9K
- Sridevi ChallapalliReno$8K
- Christopher WilsonReno$7K
- Ramprasad DandillayaLas Vegas$1.8M
- Chowdhury AhsanLas Vegas$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.